肌腱蛋白C(TNC)检测试剂盒(酶联免疫吸附试验法)
ELISA Kit for Tenascin C (TNC)
TN-C; HXB; TN; GMEM; JI; Myotendinous antigen; Neuronectin; GP 150-225; Cytotactin; Hexabrachion; Glioma-associated-extracellular matrix antigen
特异性
                        本试剂盒用于检测肌腱蛋白C(TNC),经检测与其它相似物质无明显交叉反应。
                        由于受到技术及样本来源的限制,不可能完成对所有相关或相似物质交叉反应检测,因此本试剂盒有可能与未经检测的其它物质有交叉反应。
                    
回收率
分别于定值血清及血浆样本中加入一定量的肌腱蛋白C(TNC)(加标样品),重复测定并计算其均值,回收率为测定值与理论值的比率。
| 样本 | 回收率范围(%) | 平均回收率(%) | 
| serum(n=5) | 86-98 | 94 | 
| EDTA plasma(n=5) | 80-102 | 86 | 
| heparin plasma(n=5) | 96-103 | 99 | 
精密度
                    精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100 
                    批内差:取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次,分别计算不同浓度样本的平均值及SD值。
                    批间差:选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定,每个样本使用同一试剂盒重复测定8次,分别计算不同浓度样本的平均值及SD值。
                    批内差: CV<10% 
                    批间差: CV<12% 
线性
在定值血清及血浆样本内加入适量的肌腱蛋白C(TNC),并倍比稀释成1:2,1:4,1:8,1:16的待测样本,线性范围即为稀释后样本中肌腱蛋白C(TNC)含量的测定值与理论值的比率。
| 样本 | 1:2 | 1:4 | 1:8 | 1:16 | 
| serum(n=5) | 94-101% | 83-102% | 88-95% | 90-102% | 
| EDTA plasma(n=5) | 87-103% | 95-103% | 92-99% | 93-102% | 
| heparin plasma(n=5) | 82-93% | 94-103% | 89-103% | 78-90% | 
稳定性
                    经测定,试剂盒在有效期内按推荐温度保存,其活性降低率小于5%。
                    为减小外部因素对试剂盒破坏前后检测值的影响,实验室的环境条件需尽量保持一致,尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
                
实验流程
1. 实验前标准品、试剂及样本的准备;
                            2. 加样(标准品及样本)100µL,37°C孵育1小时;
                            3. 吸弃,加检测溶液A100µL,37°C孵育1小时;
                            4. 洗板3次;
                            5. 加检测溶液B100µL,37°C孵育30分钟;
                            6. 洗板5次;
                            7. 加TMB底物90µL,37°C孵育10-20分钟;
                            8. 加终止液50µL,立即450nm读数。
实验原理
将肌腱蛋白C(TNC)抗体包被于96孔微孔板中,制成固相载体,向微孔中分别加入标准品或标本,其中的肌腱蛋白C(TNC)与连接于固相载体上的抗体结合,然后加入生物素化的肌腱蛋白C(TNC)抗体,将未结合的生物素化抗体洗净后,加入HRP标记的亲和素,再次彻底洗涤后加入TMB底物显色。TMB在过氧化物酶的催化下转化成蓝色,并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的肌腱蛋白C(TNC)呈正相关。用酶标仪在450nm波长下测定吸光度(O.D.值),计算样品浓度。
增值服务
相关产品
| 编号 | 适用物种:Homo sapiens (Human,人) | 应用(仅供研究使用,不用于临床诊断!) | 
| RPB975Hu02 | 肌腱蛋白C(TNC)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. | 
| RPB975Hu01 | 肌腱蛋白C(TNC)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. | 
| PAB975Hu01 | 肌腱蛋白C(TNC)多克隆抗体 | WB; IHC; ICC; IP. | 
| PAB975Hu02 | 肌腱蛋白C(TNC)多克隆抗体 | WB; IHC; ICC; IP. | 
| LAB975Hu71 | 肌腱蛋白C(TNC)多克隆抗体(生物素标记) | WB; IHC; ICC. | 
| MAB975Hu22 | 肌腱蛋白C(TNC)单克隆抗体 | WB; IHC; ICC; IP. | 
| MAB975Hu21 | 肌腱蛋白C(TNC)单克隆抗体 | IHC | 
| MAB975Hu23 | 肌腱蛋白C(TNC)单克隆抗体 | IHC | 
| MAB975Hu24 | 肌腱蛋白C(TNC)单克隆抗体 | IHC | 
| SEB975Hu | 肌腱蛋白C(TNC)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. | 
| LMB975Hu | 肌腱蛋白C(TNC)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. | 
参考文献
| 杂志 | 参考文献 | 
| Medical Principles and Practice | An investigation of tenascin-C levels in rheumatic mitral stenosis and their response to percutaneous mitral balloon valvuloplasty[Pubmed: 22889719] | 
| Tumor Biology | Clinical significance of serum tenascin-c levels in epithelial ovarian cancer[Springer: Source] | 
| Tumor Biology | Clinical significance of serum tenascin-C levels in breast cancer[Springer: Source] | 
| BioFactors | Tenascin-C is increased in atherothrombotic stroke patients and has an anti-inflammatory effect in the human carotid artery.[Pubmed:24823872] | 
| Connective Tissue Research | Metabolic and cytoprotective effects of in vivo peri-patellar hyaluronic acid injections in cultured tenocytes[Pubmed:25333747] | 
| K | Role of Tenascin-C in the differential diagnosis of small round blue cell tumors[Index.Php: Sdutfd] | 
| Life Sci | A new predictor of mortality in hemodialysis patients; Tenascin-C[PubMed: 26390818] | 
| Heart Research | Biomarkers Score for Patients with Mitral Stenosis: A useful conjunction with Wilkins’s Score for Early Intervention[Heartresearchopenjournal: Hroj5] | 
| Araştırmalar / Researches | Pankreas Adenokarsinomunda Serum Tenascin-C Düzeyi Potansiyel Bir Biyobelirteç Midir?[Cpdf:5C21620161255] | 
| Archives of Dermatological Research | Increased tenascin C and DKK1 in vitiligo: possible role of fibroblasts in acral and non-acral disease[Pubmed:29605863] | 
| Methods in Cell Biology | How to detect and purify tenascin-C[Pubmed:29310788] | 
| Scientific Reports | Altered transcriptional regulatory proteins in glioblastoma and YBX1 as a potential regulator of tumor invasion[Pubmed: 31358880] | 





